Literature DB >> 2577868

Mutational analysis of a phosphotransfer motif essential for v-fps tyrosine kinase activity.

M F Moran1, C A Koch, I Sadowski, T Pawson.   

Abstract

The catalytic domains of protein-tyrosine kinases such as the P130gag-fps oncoprotein contain the sequence HRDLAARN, followed thirteen residues C-terminal by DFG (P130gag-fps residues 1041-1048 and 1061-1063). These residues define a structural motif conserved among eucaryotic protein kinases (-RD----N, DFG) and shared with several procaryotic 3'aminoglycoside phosphotransferases (H-D----N, D-G). Functional analysis of mutant v-fps proteins employing bacterial and mammalian expression systems indicated that this motif is critical for P130gag-fps kinase activity and oncogenicity. In particular, conservative substitutions of the two invariant aspartates (asp1043, asp1061) with glutamate or asparagine completely eliminated enzymatic activity, suggesting that these residues are essential for catalysis. In contrast, substitution of arg1042 with glutamate decreased but did not eliminate v-fps kinase activity in bacteria. The effects of these and other amino acid substitutions within the phosphotransfer motif and at the nearby autophosphorylation site (tyr1073) of P130gag-fps indicate that these conserved residues are intrinsically essential to the execution or regulation of catalytic activity, and suggest that tight spatial constraints operate within the active centre of the v-fps tyrosine kinase domain.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2577868

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  29 in total

1.  Functional analysis of H-Ryk, an atypical member of the receptor tyrosine kinase family.

Authors:  R M Katso; R B Russell; T S Ganesan
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

2.  Src homology region 2 domains direct protein-protein interactions in signal transduction.

Authors:  M F Moran; C A Koch; D Anderson; C Ellis; L England; G S Martin; T Pawson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

3.  Development and characterization of a panel of monoclonal antibodies against the catalytic domain of the human fes proto-oncogene product.

Authors:  A van Bokhoven; H L van Duijnhoven; M Jücker; A J Roebroek; W J van de Ven
Journal:  Mol Biol Rep       Date:  1992-02       Impact factor: 2.316

4.  The common src homology region 2 domain of cytoplasmic signaling proteins is a positive effector of v-fps tyrosine kinase function.

Authors:  C A Koch; M Moran; I Sadowski; T Pawson
Journal:  Mol Cell Biol       Date:  1989-10       Impact factor: 4.272

5.  Characterization of a member of the immunoglobulin gene superfamily that possibly represents an additional class of growth factor receptor.

Authors:  Y H Chou; M J Hayman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-01       Impact factor: 11.205

6.  Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase.

Authors:  A F Wilks; A G Harpur; R R Kurban; S J Ralph; G Zürcher; A Ziemiecki
Journal:  Mol Cell Biol       Date:  1991-04       Impact factor: 4.272

7.  PDK1 regulates growth through Akt and S6K in Drosophila.

Authors:  F Rintelen; H Stocker; G Thomas; E Hafen
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

8.  Triplet puzzle: homologies of receptor heteromers.

Authors:  Alexander O Tarakanov; Kjell G Fuxe
Journal:  J Mol Neurosci       Date:  2009-12-04       Impact factor: 3.444

9.  The triplet puzzle of homologies in receptor heteromers exists also in other types of protein-protein interactions.

Authors:  Alexander O Tarakanov; Kjell G Fuxe
Journal:  J Mol Neurosci       Date:  2011-03-18       Impact factor: 3.444

10.  Nucleotide-binding properties of kinase-deficient epidermal-growth-factor-receptor mutants.

Authors:  K Cheng; J G Koland
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.